Ewing Sarcoma Treatment (PDQ®)–Health Professional Version
SECTIONS
- General Information About Ewing Sarcoma
- Cellular Classification of Ewing Sarcoma
- Stage Information for Ewing Sarcoma
- Treatment Option Overview for Ewing Sarcoma
- Treatment of Localized Ewing Sarcoma
- Treatment of Metastatic Ewing Sarcoma
- Treatment of Recurrent Ewing Sarcoma
- Late Effects of Treatment for Ewing Sarcoma
- Changes to This Summary (04/04/2018)
- About This PDQ Summary
- View All Sections
Changes to This Summary (04/04/2018)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Added text about the ADVL1622 and ADVL1615 clinical trials as treatment options under clinical evaluation for patients with recurrent Ewing sarcoma.
This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.
No hay comentarios:
Publicar un comentario